Synopsis Atenolol is a selective β 1-adrenoceptor antagonist with a duration of activity of at
least 24 hours. The scope of therapeutic use of the drug has been expanded and become …

Synopsis: Atenolol 1 is a β 1-selective (cardioselective) adrenoceptor blocking drug without
partial agonist or membrane stabilising activity. Its profile of action most closely resembles …

Synopsis: Acebutolol 1 is a cardioselective β-adrenoceptor blocking drug possessing both
partial agonist (intrinsic sympathomimetic) and membrane stabilising activity. In …

Acebutolol, a new cardioselective beta-adrenoceptor blocking agent, has been evaluated for
the treatment of hypertension. Thirty eight previously untreated male patients with essential …

The non-stimulant cardioselective beta adrenocepter antagonist atenolol has been studied
in volunteers in order to define its pharmacokinetic characteristics. Atenolol (100 and 200 …

The object of this study was to establish whether cardioselectivity of atenolol confers any
advantage over noncardioselective β‐blockade in the treatment of hypertension. A dose of …

Synopsis: Nadolol 1 is a nonselective β-adrenoceptor blocking drug without intrinsic
sympathomimetic or membrane stabilising activity. Its inherently long duration of activity …

1 The effect of atenolol, a cardioselective beta adrenoceptor antagonist, was studied in a
double‐blind crossover trial in twenty‐one carefully selected hypertensive outpatients. Each …

During the last four years we have used a new cardioselective β‐adrenergic blocking
substance, ICI 66.082 (atenolol or Tenormin®), alone or in combination with other drugs for …

The pharmacokinetics of atenolol, a new cardioselective β-adrenoceptor blocking agent,
were determined following both acute and chronic dosing in 33 hypertensive patients with …